Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Emina E. Torlakovic, PhD, MD, FCAP, University of Saskatchewan, Saskatoon, Canada, discusses the optimal use of PD-L1 immunohistochemistry (IHC) tests, suggesting high value in the early stages of clinical trial design when biomarkers have not yet been defined. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.